Testing effectiveness (Phase 2)Study completedNCT05683834
What this trial is testing
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
Who this might be right for
Epstein-Barr Virus InfectionInfectious MononucleosisHerpesvirus
National Institute of Allergy and Infectious Diseases (NIAID) 25